Tailoring resources of peripheral vascular interventions (PVIs) to those who stand to gain the most, would allow for more equitable and value-based care. One way of evaluating the benefit of PVIs in patients with symptomatic peripheral artery disease (PAD) is evaluating their health status and identifying predictors of health status response 12 months following the intervention. Patients undergoing femoropopliteal PVI between March 2005 and August 2008 from the Zilver PTX randomized trial and single-arm study were combined into a single cohort for secondary data analysis. The pre-procedural and 12-month health status was assessed by the EuroQol-5D-3L (EQ-5D). First, we evaluated the 12-month EQ-5D index (per 1-unit increase), adjusted for treatment condition and patient characteristics using a linear regression. Second, using the minimally clinically important difference (MCID) threshold for the EQ-5D index, we identified 12-month non-responders (worsened or no change) vs. responders (improved) and conducted an adjusted logistic regression model. A total of 513 patients were included (mean age 67.8 ± 9.2 years; 25.1% female), with 17.8% USA and 82.2% non-USA global enrollment sites. The MCID for the EQ-5D was 0.058. For 12-month post PVI health status, a total of 57.9% improved, 31.4% experienced no change, and 10.7% worsened, relative to their preprocedural health status. Patients who were more likely to be non-responders were more likely to have a history of carotid artery disease or were situated at a USA enrolling center. The majority of patients reported improved or stable health status after femoral-popliteal PVI. About 4 in 10 were non-responders, with the highest risk for non-response including individuals with existing carotid disease or those undergoing PVIs in the USA vs. non-USA settings.